ATE287731T1 - Inhibition von histondeacetylase zur behandlung von herzhypertrophie - Google Patents

Inhibition von histondeacetylase zur behandlung von herzhypertrophie

Info

Publication number
ATE287731T1
ATE287731T1 AT02021676T AT02021676T ATE287731T1 AT E287731 T1 ATE287731 T1 AT E287731T1 AT 02021676 T AT02021676 T AT 02021676T AT 02021676 T AT02021676 T AT 02021676T AT E287731 T1 ATE287731 T1 AT E287731T1
Authority
AT
Austria
Prior art keywords
cardiac hypertrophy
inhibition
treatment
histone deacetylase
gene expression
Prior art date
Application number
AT02021676T
Other languages
German (de)
English (en)
Inventor
Michael R Bristow
Carlin Long
Timothy A Mckinsey
Eric N Olson
Original Assignee
Univ Colorado
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado, Univ Texas filed Critical Univ Colorado
Application granted granted Critical
Publication of ATE287731T1 publication Critical patent/ATE287731T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT02021676T 2001-09-27 2002-09-27 Inhibition von histondeacetylase zur behandlung von herzhypertrophie ATE287731T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32531101P 2001-09-27 2001-09-27
US33404101P 2001-10-31 2001-10-31

Publications (1)

Publication Number Publication Date
ATE287731T1 true ATE287731T1 (de) 2005-02-15

Family

ID=26984878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02021676T ATE287731T1 (de) 2001-09-27 2002-09-27 Inhibition von histondeacetylase zur behandlung von herzhypertrophie

Country Status (8)

Country Link
US (4) US6706686B2 (enExample)
EP (1) EP1297851B1 (enExample)
JP (2) JP2003238445A (enExample)
AT (1) ATE287731T1 (enExample)
DE (1) DE60202727T2 (enExample)
DK (1) DK1297851T3 (enExample)
ES (1) ES2236415T3 (enExample)
PT (1) PT1297851E (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028020A2 (en) * 1998-11-10 2000-05-18 Board Of Regents, The University Of Texas System Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
JP2001149081A (ja) * 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040077083A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070104688A1 (en) * 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
US20040171118A1 (en) * 2003-02-13 2004-09-02 City Of Hope Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs
US7375228B2 (en) * 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
MXPA05012619A (es) * 2003-05-21 2006-02-08 Univ Texas Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.
JP2007504131A (ja) * 2003-08-29 2007-03-01 エートン ファーマ インコーポレーティッド 癌の組み合わせ処置法
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050283841A1 (en) * 2004-02-02 2005-12-22 Mckinsey Timothy A Inhibition of protein kinase C-related kinase (PRK) as a treatment for cardiac hypertrophy and heart failure
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
US20050288215A1 (en) * 2004-04-05 2005-12-29 Mckinsey Timothy A Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
EP1740945B1 (en) 2004-04-07 2018-09-19 Ncardia AG Non-invasive, in vitro functional tissue assay systems
ES2354997T3 (es) 2004-05-11 2011-03-21 Axiogenesis Ag Ensayo para el descubrimiento de fármacos basado en células diferenciadas in vitro.
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
US20060110390A1 (en) * 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
WO2006060382A2 (en) * 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7772245B2 (en) 2005-02-14 2010-08-10 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
WO2006094068A2 (en) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP1901764A1 (en) * 2005-07-14 2008-03-26 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
WO2007011626A2 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20090012066A1 (en) * 2005-08-10 2009-01-08 Novartis Ag Method of Use of Deacetylase Inhibitors
US20070129290A1 (en) * 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
US7863414B2 (en) 2005-11-18 2011-01-04 The Board Of Regents Of The University Of Texas Systems Methods of treatment and uses for CaMKII and its interaction with HDACs and calpain
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20100226857A1 (en) * 2006-03-29 2010-09-09 Jeannine Strobl Tumor cell differentiation agents as chemical inhibitors and treatments for intracellular parasites
KR20080108156A (ko) * 2006-04-06 2008-12-11 노파르티스 아게 유기 화합물의 조합물
AU2007238600B2 (en) * 2006-04-13 2012-01-19 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
WO2007145704A2 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
CN101801994A (zh) * 2006-12-29 2010-08-11 格洛斯特制药公司 制备Romidepsin
AU2007342030B2 (en) * 2006-12-29 2013-08-15 Celgene Corporation Romidepsin-based treatments for cancer
US9884031B2 (en) * 2007-05-09 2018-02-06 The Trustees Of The University Of Pennsylvania Use of HDAC inhibitors for treatment of cardiac rhythm disorders
US7737175B2 (en) * 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
WO2009048540A1 (en) * 2007-10-05 2009-04-16 U.S. Department Of Veterans Affairs Office Of General Counsel - Psg Iv (024) Method and composition for treating heart failure
WO2009089598A2 (en) * 2008-01-18 2009-07-23 Katholieke Universiteit Leuven Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
WO2010039697A2 (en) * 2008-09-30 2010-04-08 Gilead Sciences, Inc. Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy
WO2011032088A1 (en) 2009-09-11 2011-03-17 Arca Biopharma, Inc. Polymorphisms in the pde3a gene
EP2593123B1 (en) 2010-07-12 2019-09-04 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
RS58895B1 (sr) 2010-10-13 2019-08-30 Medivir Ab Farmaceutska formulacija za inhibitore histonske deacetilaze
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CA3156303A1 (en) * 2019-10-03 2021-04-08 Tenaya Therapeutics, Inc. 5-fluoronicotinamide derivatives and uses thereof
WO2021127643A1 (en) 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
CN116942822A (zh) * 2023-06-12 2023-10-27 深圳大学 Hdac2在治疗室性心律失常中的应用
CN118766882B (zh) * 2024-09-12 2025-02-21 北京大学第三医院（北京大学第三临床医学院） 用于治疗心血管疾病的制剂及其应用和制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5968981A (en) * 1995-07-28 1999-10-19 The Regents Of The University Of California Retinoid suppression of ventricular muscle cell hypertrophy
JP2002528391A (ja) 1998-10-19 2002-09-03 メチルジェン，インク． 組合せ治療による遺伝子発現の修飾
JP4269041B2 (ja) 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
CA2366408A1 (en) 1999-05-03 2000-11-30 Methylgene, Inc. Inhibition of histone deacetylase
JP2003507076A (ja) 1999-08-20 2003-02-25 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 心臓の遺伝子発現の調節におけるｈｄａｃ４およびｈｄａｃ５
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
WO2001017514A1 (en) * 1999-09-03 2001-03-15 The Salk Institute For Biological Studies Modulation of gene expression by modulating histone acetylation
JP2003508501A (ja) 1999-09-07 2003-03-04 コンジュケム，インコーポレーテッド 生物学的結合のための肺送達
ES2287033T3 (es) 1999-09-08 2007-12-16 Sloan-Kettering Institute For Cancer Research Estructura cristalina de una desacetilasa e inhibidores de la misma.
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
DE60026733T2 (de) 1999-12-08 2006-11-02 AXYS Pharmaceuticals, Inc., South San Francisco Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung
CA2408385A1 (en) 2000-03-24 2001-09-24 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
CA2404002A1 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
EP1170008A1 (en) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
AU9013101A (en) 2000-09-29 2002-04-22 Prolifix Ltd Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
JP2004509941A (ja) 2000-09-29 2004-04-02 プロリフィクス　リミテッド Ｈｄａｃインヒビターとしてのアミド結合を含むカルバミン酸化合物
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
JP2004520027A (ja) 2000-12-20 2004-07-08 ノバルティス アクチエンゲゼルシャフト ヒストンデアセチラーゼ関連遺伝子およびタンパク質
AR035513A1 (es) 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy

Also Published As

Publication number Publication date
US6946441B2 (en) 2005-09-20
DE60202727T2 (de) 2005-12-29
US20040186049A1 (en) 2004-09-23
DE60202727D1 (de) 2005-03-03
JP2003238445A (ja) 2003-08-27
PT1297851E (pt) 2005-06-30
US20030144340A1 (en) 2003-07-31
US20060069014A1 (en) 2006-03-30
EP1297851A1 (en) 2003-04-02
US6706686B2 (en) 2004-03-16
DK1297851T3 (da) 2005-05-30
ES2236415T3 (es) 2005-07-16
JP2010001311A (ja) 2010-01-07
EP1297851B1 (en) 2005-01-26
US20060025333A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
DE60202727D1 (de) Inhibition von Histondeacetylase zur Behandlung von Herzhypertrophie
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DK1233958T3 (da) Hæmmere af histondeacetylase
ATE463490T1 (de) Histondeacetylase-hemmer
ATE489360T1 (de) Inhibitoren der histon-deacetylase
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
MXPA04002397A (es) Inhibidores de histona deacetilasa.
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
DK1163208T3 (da) Caspaseinhibitorer og anvendelser deraf
DK1480961T3 (da) Glutaminylbaserede DPIV-inhibitorer
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
ATE442141T1 (de) Verfahren zur behandlung von stoffwechselerkrankungen mit malonyl-coa- decarboxylase-hemmern
ATE275411T1 (de) Verwendung von phyllanthus zur behandlung von chronisch entzündlichen und fibrotischen prozessen
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
ATE366569T1 (de) Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1297851

Country of ref document: EP

REN Ceased due to non-payment of the annual fee